The common data model (CDM) has found widespread application in healthcare studies, but its utilization in cancer research has been limited. This article describes the development and implementation strategy for Cancer Clinical Library Databases (CCLDs), which are standardized cancer-specific databases established under the Korea-Clinical Data Utilization Network for Research Excellence (K-CURE) project by the Korean Ministry of Health and Welfare. Fifteen leading hospitals and fourteen academic associations in Korea are engaged in constructing CCLDs for 10 primary cancer types. For each cancer type-specific CCLD, cancer data experts determine key clinical data items essential for cancer research, standardize these items across cancer types, and create a standardized schema. Comprehensive clinical records covering diagnosis, treatment, and outcomes, with annual updates, are collected for each cancer patient in the target population, and quality control is based on six-sigma standards. To protect patient privacy, CCLDs follow stringent data security guidelines by pseudonymizing personal identification information and operating within a closed analysis environment. Researchers can apply for access to CCLD data through the K-CURE portal, which is subject to Institutional Review Board and Data Review Board approval. The CCLD is considered a pioneering standardized cancer-specific database, significantly representing Korea’s cancer data. It is expected to overcome limitations of previous CDMs and provide a valuable resource for multicenter cancer research in Korea.

The common data model (CDM) has found widespread application in healthcare studies, but its utilization in cancer research has been limited. This article describes the development and implementation strategy for Cancer Clinical Library Databases (CCLDs), which are standardized cancer-specific databases established under the Korea-Clinical Data Utilization Network for Research Excellence (K-CURE) project by the Korean Ministry of Health and Welfare. Fifteen leading hospitals and fourteen academic associations in Korea are engaged in constructing CCLDs for 10 primary cancer types. For each cancer type-specific CCLD, cancer data experts determine key clinical data items essential for cancer research, standardize these items across cancer types, and create a standardized schema. Comprehensive clinical records covering diagnosis, treatment, and outcomes, with annual updates, are collected for each cancer patient in the target population, and quality control is based on six-sigma standards. To protect patient privacy, CCLDs follow stringent data security guidelines by pseudonymizing personal identification information and operating within a closed analysis environment. Researchers can apply for access to CCLD data through the K-CURE portal, which is subject to Institutional Review Board and Data Review Board approval. The CCLD is considered a pioneering standardized cancer-specific database, significantly representing Korea’s cancer data. It is expected to overcome limitations of previous CDMs and provide a valuable resource for multicenter cancer research in Korea.

The common data model (CDM) has found widespread application in healthcare studies, but its utilization in cancer research has been limited. This article describes the development and implementation strategy for Cancer Clinical Library Databases (CCLDs), which are standardized cancer-specific databases established under the Korea-Clinical Data Utilization Network for Research Excellence (K-CURE) project by the Korean Ministry of Health and Welfare. Fifteen leading hospitals and fourteen academic associations in Korea are engaged in constructing CCLDs for 10 primary cancer types. For each cancer type-specific CCLD, cancer data experts determine key clinical data items essential for cancer research, standardize these items across cancer types, and create a standardized schema. Comprehensive clinical records covering diagnosis, treatment, and outcomes, with annual updates, are collected for each cancer patient in the target population, and quality control is based on six-sigma standards. To protect patient privacy, CCLDs follow stringent data security guidelines by pseudonymizing personal identification information and operating within a closed analysis environment. Researchers can apply for access to CCLD data through the K-CURE portal, which is subject to Institutional Review Board and Data Review Board approval. The CCLD is considered a pioneering standardized cancer-specific database, significantly representing Korea’s cancer data. It is expected to overcome limitations of previous CDMs and provide a valuable resource for multicenter cancer research in Korea.

The prevalence of young-onset type 2 diabetes is increasing rapidly worldwide along with the incidence of obesity, including in Korea. Compared with later onset type 2 diabetes, patients with young-onset type 2 diabetes have a higher risk of microvascular complication, macrovascular complication, and disease-related mortality. Thus, integrated attention and management of associated pathobiological, socioeconomic, and mental health factors are needed. Based on the very few evidence-based studies in management, in this review, we describe strategies for the integrated management for young-onset type 2 diabetes.

The prevalence of young-onset type 2 diabetes is increasing rapidly worldwide along with the incidence of obesity, including in Korea. Compared with later onset type 2 diabetes, patients with young-onset type 2 diabetes have a higher risk of microvascular complication, macrovascular complication, and disease-related mortality. Thus, integrated attention and management of associated pathobiological, socioeconomic, and mental health factors are needed. Based on the very few evidence-based studies in management, in this review, we describe strategies for the integrated management for young-onset type 2 diabetes.

The prevalence of young-onset type 2 diabetes is increasing rapidly worldwide along with the incidence of obesity, including in Korea. Compared with later onset type 2 diabetes, patients with young-onset type 2 diabetes have a higher risk of microvascular complication, macrovascular complication, and disease-related mortality. Thus, integrated attention and management of associated pathobiological, socioeconomic, and mental health factors are needed. Based on the very few evidence-based studies in management, in this review, we describe strategies for the integrated management for young-onset type 2 diabetes.

The prevalence of young-onset type 2 diabetes is increasing rapidly worldwide along with the incidence of obesity, including in Korea. Compared with later onset type 2 diabetes, patients with young-onset type 2 diabetes have a higher risk of microvascular complication, macrovascular complication, and disease-related mortality. Thus, integrated attention and management of associated pathobiological, socioeconomic, and mental health factors are needed. Based on the very few evidence-based studies in management, in this review, we describe strategies for the integrated management for young-onset type 2 diabetes.

The prevalence of young-onset type 2 diabetes is increasing rapidly worldwide along with the incidence of obesity, including in Korea. Compared with later onset type 2 diabetes, patients with young-onset type 2 diabetes have a higher risk of microvascular complication, macrovascular complication, and disease-related mortality. Thus, integrated attention and management of associated pathobiological, socioeconomic, and mental health factors are needed. Based on the very few evidence-based studies in management, in this review, we describe strategies for the integrated management for young-onset type 2 diabetes.

Purpose: The coronavirus disease 2019 (COVID-19) pandemic has led to significant global casualties. This study examines the postoperative impact of COVID-19 on patients who underwent gastrointestinal surgery, considering their heightened vulnerability to infections and increased morbidity and mortality risk. Methods: This retrospective observational study was conducted at a tertiary center and patients who underwent gastrointestinal surgery between January 2022 and February 2023 were included. Postoperative COVID-19 infection was defined as the detection of severe acute respiratory syndrome coronavirus 2 RNA by RT-PCR within 14 days after surgery. Propensity score matching was performed including age, sex, American Society of Anesthesiology physical status classification, and emergency operation between the COVID-19-negative (–) and -positive (+) groups. Results: Following 1:2 propensity score matching, 21 COVID-19(+) and 42 COVID-19(–) patients were included in the study. In the COVID-19(+) group, the postoperative complication rate was significantly higher (52.4% vs. 23.8%, P = 0.023).Mechanical ventilator requirement, intensive care unit (ICU) admission, and readmission rate did not significantly differ between the 2 groups. The median length of ICU (19 days vs. 4 days, P < 0.001) and hospital stay (18 vs. 8 days, P = 0.015) were significantly longer in the COVID-19(+) group. Patients with COVID-19 had a 2.4 times higher relative risk (RR) of major complications than patients without COVID-19 (RR, 2.37; 95% confidence interval, 1.254–4.467; P = 0.015). Conclusion COVID-19 infection during the postoperative period in gastrointestinal surgery may have adverse outcomes which may increase the risk of major complications. Preoperative COVID-19 screening and protocols for COVID-19 prevention in surgical patients should be maintained.